Results 91 to 100 of about 14,652 (127)

Comparative effects of empagliflozin and metformin on metabolic dysfunction in polycystic ovary syndrome, a double blinded randomized control feasibility trial. [PDF]

BMC Womens Health
Sharif H, Arsalan S, Rehman N, Muzammil A, Hatif F, Wasti F, Rehman S, Mohsin N, Nasir R, Omair W.   +9 more
europepmc   +1 more source

Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications. [PDF]

Pharmaceutics
Koo N, Lee EJ, Chang JE, Lee KR, Chae YJ.   +4 more
europepmc   +1 more source

Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome. [PDF]

J Pharm Pharm Sci
Shafaati T, Greenwell AA, Saed CT, Tabatabaei Dakhili SA, Chan JSF, Dong L, Stenlund MJ, Ferrari SR, Han R, Kruger J, Eaton F, Gopal K, Davidge ST, Oudit GY, Ussher JR.   +14 more
europepmc   +1 more source

Evaluating the Beneficial Effect of Empagliflozin in Reducing Hospitalisation for Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review. [PDF]

Cureus
Soni A, Lawal OP, Oyovwi JO, Olaniyi HI, Anosike WO, Orobator ET, Gabriels N, Ghori IAK, Olaniyi AO.   +8 more
europepmc   +1 more source

Impact of Empagliflozin on Glomerular Hyperfiltration and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of DINAMO. [PDF]

Clin J Am Soc Nephrol
Bjornstad P, Danne T, Klingensmith GJ, Schueler E, Tartakovsky I, Marquard J, Zeitler P, Willi S, Laffel LM.   +8 more
europepmc   +1 more source

Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection. [PDF]

Biomedicines
Aazar RFM, Arzouni R, Nicolaou PA.
europepmc   +1 more source

SGLT-2 inhibitors in prevention of chemotherapy-induced cardiotoxicity: systematic review and meta-analysis. [PDF]

Eur Heart J Open
Rafique S, Buhnerkempe M, Elmasry Y, Kulkarni A, Rao K, Bhattarai M.   +5 more
europepmc   +1 more source

Empagliflozin Improves Cardiomyocyte Function in Phospholamban-R14del Cardiomyopathy by Regulating Calcium/Calmodulin-Stimulated Protein Kinase II Activity and Apoptosis. [PDF]

J Am Heart Assoc
Hnatiuk AP, Li AW, Vecci BE, Staudt DW, Serrano R, Gao X, Tran PPQ, Mercola M.   +7 more
europepmc   +1 more source

Empagliflozin and Dapagliflozin Outcomes in Heart Failure.

JAMA Netw Open
Bu S, Jung MH, Lee D, Hwang YM, Cho JS, Yi JE, Kim H, Kim S, Chung D, Shin DH, Aung N, Ahn HS.   +11 more
europepmc   +1 more source